7月28日，SELLAS Life Sciences盘中下跌14.89%，报9.62美元/股，成交额4344.16万美元。
消息面上，思路迪医药公告其与SELLAS Life Sciences在香港国际仲裁中心的仲裁案已获最终裁决，SELLAS提出的所有仲裁主张被全面驳回，且SELLAS须承担对方仲裁相关开支合计798.3万港元，需于8月7日前缴付。该仲裁虽不影响双方许可协议的履行，但仲裁全面败诉对市场信心构成压力。此前该股已连续承压，7月24日曾单日下跌逾8%，振幅超10%，近期累计回撤幅度显著。
SELLAS Life Sciences Group, Inc.是一家临床后期生物制药公司，专注于开发针对多种癌症适应症的新疗法，主要候选产品包括针对急性髓系白血病的Galinpepimut-S及CDK9抑制剂SLS009。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.